% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Ster:300745,
      author       = {N. C. Støer and E. Botteri and K. Lindemann and H.
                      Langseth and R. Turzanski-Fortner$^*$},
      title        = {{L}ow-dose aspirin and non-aspirin non-steroidal
                      anti-inflammatory drugs and epithelial ovarian cancer
                      survival: a registry-based cohort study in {N}orway.},
      journal      = {BMC cancer},
      volume       = {25},
      number       = {1},
      issn         = {1471-2407},
      address      = {London},
      publisher    = {BioMed Central},
      reportid     = {DKFZ-2025-00905},
      pages        = {807},
      year         = {2025},
      note         = {#LA:C020#},
      abstract     = {Aspirin and non-aspirin non-steroidal anti-inflammatory
                      drugs (NA-NSAID) have been associated with improved survival
                      in individuals with epithelial ovarian cancer (EOC);
                      however, findings to date are inconsistent.We conducted a
                      registry-based cohort study evaluating survival following an
                      incident invasive EOC diagnosis including individuals
                      diagnosed between 2004-2018 (n = 4325; n = 2206 deaths; n =
                      1973 EOC deaths). Evaluated exposures were low-dose aspirin
                      and NA-NSAIDs. Two primary post-diagnosis exposure windows
                      were evaluated: fixed post-diagnostic baseline exposure ≤
                      305 days after diagnosis (use, non-use) and updated
                      'time-varying' exposure (never, past, current use;
                      cumulative defined daily dose (DDD)). Pre-diagnostic
                      exposure (use, non-use) was further evaluated. Multivariable
                      Cox-proportional hazard models were used to estimate hazard
                      ratios (HRs) and $95\%$ confidence intervals $[95\%$ CIs].
                      The primary outcome was cause-specific survival. Restricted
                      mean survival time (RMST) in exposure groups was estimated
                      at 5 years following start of follow-up.Baseline
                      post-diagnosis aspirin use was not associated with survival
                      following an EOC diagnosis (e.g., use vs. no use: aspirin,
                      HR = 1.02 $[95\%$ CI = 0.84-1.24]). Inverse associations
                      were observed between current aspirin use post-diagnosis and
                      survival in the time-varying exposure models (HR 0.68
                      [0.57-0.81]), and with higher post-diagnosis cumulative DDD
                      of aspirin. Findings for NA-NSAIDs were less consistent. No
                      associations were observed for pre-diagnostic use. Results
                      for overall survival were similar to those for
                      cause-specific survival. Compared to never use,
                      post-diagnosis low-dose aspirin use was associated with a
                      longer RMST (e.g., ever vs. never use, difference in RMST =
                      2.67 months).This study provides further evidence of a
                      potential beneficial effect of post-diagnosis low-dose
                      aspirin use for ovarian cancer survival.},
      keywords     = {Humans / Female / Aspirin: administration $\&$ dosage /
                      Aspirin: therapeutic use / Anti-Inflammatory Agents,
                      Non-Steroidal: administration $\&$ dosage /
                      Anti-Inflammatory Agents, Non-Steroidal: therapeutic use /
                      Carcinoma, Ovarian Epithelial: mortality / Carcinoma,
                      Ovarian Epithelial: drug therapy / Registries: statistics
                      $\&$ numerical data / Norway: epidemiology / Middle Aged /
                      Aged / Ovarian Neoplasms: mortality / Ovarian Neoplasms:
                      drug therapy / Cohort Studies / Adult / Proportional Hazards
                      Models / Aspirin (Other) / Non-aspirin NSAIDs (Other) /
                      Ovarian cancer (Other) / Survival (Other) / Aspirin (NLM
                      Chemicals) / Anti-Inflammatory Agents, Non-Steroidal (NLM
                      Chemicals)},
      cin          = {C020},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40307814},
      doi          = {10.1186/s12885-025-14168-y},
      url          = {https://inrepo02.dkfz.de/record/300745},
}